Vascular Biogenics Company Profile (NASDAQ:VBLT)

Analyst Ratings

Consensus Ratings for Vascular Biogenics (NASDAQ:VBLT) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $16.50 (308.42% upside)

Analysts' Ratings History for Vascular Biogenics (NASDAQ:VBLT)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016HC WainwrightInitiated CoverageBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper Jaffray Cos.Reiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2015Deutsche Bank AGBoost Price Target$12.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Vascular Biogenics (NASDAQ:VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Biogenics (NASDAQ:VBLT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vascular Biogenics (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ:VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Vascular Biogenics (NASDAQ:VBLT)
DateHeadline
07/20/16 09:58 AMVascular Biogenics Ltd. (NASDAQ:VBLT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 06:42 AMTrading Performance and Target Watch for Vascular Biogenics Ltd. (NASDAQ:VBLT) - Press Telegraph
07/17/16 06:48 AMStrong Sell Calls For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire
07/14/16 10:45 AMVascular Biogenics Ltd. (VBLT) Updated Price Targets - FTSE News
07/13/16 07:25 PMAnalyst Target and Average Rating Watch: Vascular Biogenics Ltd. (NASDAQ:VBLT) - Press Telegraph
07/09/16 06:18 PMIs $22 Within Reach For Vascular Biogenics Ltd. (NASDAQ:VBLT)? - Investor Newswire
07/08/16 09:53 AMNew Broker Ratings For Vascular Biogenics Ltd. (VBLT) - FTSE News
07/04/16 06:44 AMVascular Biogenics Ltd (NASDAQ:VBLT) target price raised to $11 as covered today by H.C. Wainwright - Breaking Finance News
07/03/16 06:13 PMVascular Biogenics Ltd (NASDAQ:VBLT) target price raised to $11 as covered today by H.C. Wainwright
07/02/16 09:01 AM7 Analyst Stock Picks Under $10 With Massive Upside Calls -
07/01/16 09:44 AMHC Stocks Growth: Vascular Biogenics Ltd (NASDAQ:VBLT), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release)
06/30/16 07:17 PMCan Vascular Biogenics Ltd. (NASDAQ:VBLT) Meet Analysts Expectations? - Stocks Daily
06/30/16 07:17 PMAnalyst Rating Update on Vascular Biogenics Ltd. (VBLT) - TheFounders Daily
06/29/16 06:59 PMH.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics
06/28/16 07:00 PMH.C. Wainwright Starts Vascular Biogenics Ltd (VBLT) at Buy - StreetInsider.com
06/28/16 06:07 AMCoverage initiated on VBL Therapeutics by H.C. Wainwright -
06/27/16 06:53 PMHot Stocks: Neuralstem, Inc. (NASDAQ:CUR), Vascular Biogenics Ltd. (NASDAQ:VBLT), Accelerate Diagnostics, Inc ... - KC Register
06/27/16 06:39 AMNext Weeks Broker Price Targets For Vascular Biogenics Ltd. (VBLT) - Fiscal Standard
06/26/16 06:38 AMStrong Sell Calls Recommendations For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire
06/22/16 06:46 AMVascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Rating Consensus - TheFounders Daily
06/21/16 06:29 AMVascular Biogenics Ltd. (VBLT) Analyst Price Targets For The Coming Week - Fiscal Standard
06/21/16 06:19 AMVBL Therapeutics Announces Appointment of Dr. Rachel W. Humphrey to Head of the Scientific Advisory Board - [at noodls] - TEL AVIV, Israel, June 21, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
06/17/16 09:45 AMVascular Biogenics Ltd. (VBLT) Current Analyst Ratings - Fiscal Standard
06/16/16 11:49 AMVascular Biogenics Ltd. Closes $24 Million Registered Direct Offering - [at noodls] - TEL AVIV, Israel, June 16, 2016 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ('VBL Therapeutics' or the 'Company') (NASDAQ:VBLT) announced that on June 10, 2016, it closed its previously announced sale ...
06/13/16 10:03 AMStock's Earnings Analysis: STORE Capital Corporation (NYSE:STOR), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle
06/10/16 10:12 AMInvestors Focused Stocks: Array BioPharma Inc. (NASDAQ:ARRY) , Vascular Biogenics Ltd. (NASDAQ:VBLT) - Street Updates
06/09/16 10:12 AMEarnings Analysis to Watch: Brookdale Senior Living Inc. (NYSE:BKD), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle
06/08/16 05:02 PMVascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/07/16 07:22 PMServices Stocks Try To Grab Potentials- Vascular Biogenics (NASDAQ:VBLT), Array BioPharma (NASDAQ:ARRY) - Seneca Globe
06/07/16 01:42 PM8 Biggest Mid-Day Losers For Tuesday - DryShips Inc. (NASDAQ: DRYS) shares fell 44.07 percent to $1.32 after the company announced that it has breached some financial covenants. The company also said that it has yet to make final balloon installments on three matured banking facilities and three lenders have declared event a default. Vascular Biogenics Ltd (NASDAQ: VBLT) shares fell 12.55 percent to $5.99 after surging 72.54 percent on Monday. The company reported a $24 million registered direct offering. Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares 12.06 percent to $25.37 after ...Full story available on Benzinga.com
06/07/16 09:58 AMWorth Watching Stocks Roundup: Vascular Biogenics Ltd (NASDAQ:VBLT), Gerdau SA (ADR) (NYSE:GGB) - NYSE Journal (press release)
06/07/16 09:58 AMWatch List - Cisco Systems, (NASDAQ:CSCO), Vascular Biogenics, (NASDAQ:VBLT) - Wall Street 24
06/07/16 09:58 AMVascular Biogenics Ltd (NASDAQ:VBLT) & ProNAi Therapeutics (NASDAQ:DNAI) Healthcare Stocks in the News - Wall Street 24
06/07/16 09:58 AMEarnings Overview: Globalstar Inc. (NYSEMKT:GSAT), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle
06/07/16 07:18 AMVBL Therapeutics to Present Today at the 2016 BIO International Convention - [at noodls] - Dror Harats, CEO will discuss ASCO newly-reported VB-111 clinical data in Ovarian Cancer and rGBM TEL AVIV, Israel, June 07, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced that Chief ...
06/06/16 07:15 PMVascular Biogenics Surges 80% Off Double Catalyst - Benzinga
06/06/16 12:42 PM9 Biggest Mid-Day Gainers For Monday - Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares jumped 105.5 percent to $2.12 amid news of merger with Zone Technologies. Vascular Biogenics Ltd (NASDAQ: VBLT) shares rose 81.11 percent to $7.19 in pre-market trading after the company reported data that showed significant overall survivor benefit in rGBM patients receiving VB-111 versus historical Avastin. Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) shares climbed 65.15 percent to $7.27 after the company issued updated data from its DNA damage response program on seliciclib and sapacitabine combo in patients with solid ...Full story available on Benzinga.com
06/06/16 11:40 AMVascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Vascular Biogenics (VBLT) is soaring in Monday's trading after reporting wonderful Phase I/II trial data for an ovarian cancer treatment.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/06/vascular-biogenics-ltd-vblt-stock/">Vascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
06/06/16 11:15 AMVascular Biogenics Ltd. (VBLT) Is Up Sharply On Study Results - RTT News
06/06/16 10:21 AMHere’s Why These Five Stocks Are Surging Today -
06/06/16 09:59 AMVascular Biogenics (VBLT) Stock Spikes on Positive Trial Results -
06/06/16 07:55 AMWhy Vascular Biogenics Is One of the Biggest Winners From ASCO So Far -
06/06/16 07:40 AMVascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results -
06/06/16 06:18 AMVB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer - [at noodls] - VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042) 60% (9 of 15) durable response rate (as measured by reduction ...
06/03/16 07:50 PMVascular Biogenics Ltd. (VBLT) Is Up On Phase 2 Study Results - RTT News
06/03/16 03:15 PMClinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data - [at noodls] - VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous exposure ...
06/03/16 03:05 PM4:05 pm VBL Therapeutics Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint: Clinical Data Presented at ASCO demonstrate significant overall survival benefit vs. historical Avastin -
06/03/16 10:09 AMStrong Sell Calls Count For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire
06/02/16 07:38 PMBroker Watchlist: Vascular Biogenics Ltd. (VBLT) - Share Trading News - Broker Watchlist: Vascular Biogenics Ltd. (VBLT)Share Trading News01/22/2015 – Vascular Biogenics Ltd. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 19 price target on the stock. The share price of Vascular Biogenics Ltd. (VBLT) was up +1.14% during the last trading session, with a ...
05/31/16 08:02 AMStock Review and Earnings Check on Vascular Biogenics Ltd. (NASDAQ:VBLT) - HNN - Stock Review and Earnings Check on Vascular Biogenics Ltd. (NASDAQ:VBLT)HNNCurrently, sell-side analysts are expecting Vascular Biogenics Ltd. (NASDAQ:VBLT) to report quarterly EPS of $-0.2. The company's next earnings report is expected to be published on or around 2016-08-11 for the period ending on 2016-06-30. The company ...and more »

Social

About Vascular Biogenics

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBLT
  • CUSIP:
Key Metrics:
  • Previous Close: $4.04
  • 50 Day Moving Average: $4.34
  • 200 Day Moving Average: $3.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $90.80M
  • Beta: -3.39
  • Current Year EPS Consensus Estimate: $-0.82 EPS
  • Next Year EPS Consensus Estimate: $-0.84 EPS
Additional Links:
Vascular Biogenics (NASDAQ:VBLT) Chart for Monday, July, 25, 2016